Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
12 Results for "
human acute monocytic leukemia
" in MedChemExpress (MCE) Product Catalog:
Products (12)
12 Results for "human acute monocytic leukemia" in MCE Product Catalog:
6
6 Publications Verification
Target:
Research Areas:
SETDB1-TTD-IN-1 is a SETDB1 methyltransferase activator and SETDB1-TTD competitive inhibitor (Kd of 88 nM), and selectivity for SETDB1-TTD over other tudor and bromodomain proteins. SETDB1-TTD-IN-1 stimulates methyltransferase activity via increased catalytic activity, promotes Akt1 Lys64 methylation, Akt1 Thr308 phosphorylation and activation. SETDB1-TTD-IN-1 prevents SETDB1-TTD-histone H3 peptide association, induces global gene expression changes, exhibits cellular target engagement, and acts as a tool compound for SETDB1-TTD function exploration. SETDB1-TTD-IN-1 can be used for the research of breast cancer .
1
1 Cited Publications
Target:
Research Areas:
PROTAC RIPK degrader-2 is a non-peptidic PROTAC degrader targeting RIPK2, with a DC50 of 1.5 nM. PROTAC RIPK degrader-2 recruits VHL or cereblon E3 ubiquitin ligases, induces ubiquitination and proteasomal degradation of RIPK2, acts via substoichiometric catalysis, and inhibits downstream pro-inflammatory signaling pathways. PROTAC RIPK degrader-2 inhibits the NOD2/RIPK2 pathway and suppresses MDP (HY-127090)-stimulated TNFα release in human whole blood. PROTAC RIPK degrader-2 can be used in studies related to acute monocytic leukemia and glucose metabolism .
1
1 Cited Publications
Cat. No.: HY-76293
CAS No.: 331963-29-2
I2906 is an orally active isocitrate lyase (ICL) inhibitor with a Mycobacterium tuberculosis IC50 of 134.3 μg/mL. I2906 inhibits the growth of Mycobacterium tuberculosis. I2906 can be used for the research of tuberculosis .
TIM-3-IN-2 is a TIM-3 inhibitor. TIM-3-IN-2 blocks the interactions of TIM-3 with PtdSer, CEACAM1 and Gal-9, and inhibits the immunosuppressive function of TIM-3. TIM-3-IN-2 restores IFNγ release from peripheral blood mononuclear cells. TIM-3-IN-2 inhibits the proliferation of acute myeloid leukemia cells. TIM-3-IN-2 can be used for the research of acute myeloid leukemia .
Cat. No.: HY-162608
CAS No.: 3052553-20-2
PROTAC JAK1 degrader 1 is a JAK1 PROTAC degrader with a DC50 of 214 nM and an IC50 of 5.2 nM. PROTAC JAK1 degrader 1 inhibits the downstream JAK-STAT signaling pathway by degrading JAK1. PROTAC JAK1 degrader 1 exhibits antiproliferative activity in cells. PROTAC JAK1 degrader 1 can be used for research on leukemia .
Cat. No.: HY-N8390
CAS No.: 168293-15-0
Target:
Cat. No.: HY-147609
CAS No.: 2765301-60-6
CSF1R-IN-8 (Compound 22) is a CSF-1R inhibitor with an IC50 of 0.012 μM .
Cat. No.: HY-147611
CAS No.: 2765301-88-8
CSF1R-IN-10 (Compound 48) is a CSF-1R inhibitor with an IC50 of 0.005 μM .
Cat. No.: HY-147610
CAS No.: 2765301-84-4
CSF1R-IN-9 (Compound 46) is a CSF-1R inhibitor with an IC50 of 0.028 μM .
Cat. No.: HY-208740
CAS No.: 2488951-93-3
Target:
Research Areas:
PKCζ-IN-2 is an orally active, selective PKCζ inhibitor with an IC50 of 0.1 nM. As an anti-inflammatory agent, PKCζ-IN-2 reduces joint swelling and ameliorates disease progression in a mouse collagen-induced arthritis model. PKCζ-IN-2 can be used for the research of rheumatoid arthritis .
Cat. No.: HY-W207224
CAS No.: 287177-12-2
Target:
Research Areas:
F1386-0303 is a highly selective MAP4K4 inhibitor with an IC50 of 34 nM against human targets. F1386-0303 exerts cardiomyocyte protective and function-preserving effects through mechanisms such as alleviating oxidative stress, inhibiting caspases, and maintaining mitochondrial membrane potential, while it does not interfere with the activity of Doxorubicin (HY-15142A) in cancer cells. F1386-0303 is rapidly cleared and has no bioavailability in mice, but it is well-suited as a tool compound for target validation. F1386-0303 can be applied to studies related to cardiac ischemia-reperfusion injury, Doxorubicin-induced cardiotoxicity, myocardial infarction and other related conditions .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
